| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |